{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"24"}],"units":"Participants"}],"description":"HCT failure will be defined as graft rejection (defined as \\< 5% donor T-cell chimerism) or disease progression within 200 days of transplant.","groups":[{"description":"Arm A - patients with MPD or MDS-RA/RARS Dose Level 1 - 300 cGy TBI\n\nNONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.\n\nPBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.\n\nIMMUNOSUPPRESSION:\n\nMatched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.\n\nUnrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96.","id":"OG000","title":"Arm A - Dose Level 1"},{"description":"Arm A - patients with MPD or MDS-RA/RARS Dose Level 2 - 400 cGy TBI\n\nNONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.\n\nPBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.\n\nIMMUNOSUPPRESSION:\n\nMatched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.\n\nUnrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96.","id":"OG001","title":"Arm A - Dose Level 2"},{"description":"Arm A - patients with MPD or MDS-RA/RARS Dose Level 3 - 450 cGy TBI\n\nNONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.\n\nPBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.\n\nIMMUNOSUPPRESSION:\n\nMatched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.\n\nUnrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96.","id":"OG002","title":"Arm A - Dose Level 3"},{"description":"Arm B - patients with MDS-RAEB or CMML Dose Level 1 - 300 cGy TBI\n\nNONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.\n\nPBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.\n\nIMMUNOSUPPRESSION:\n\nMatched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.\n\nUnrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96.","id":"OG003","title":"Arm B - Dose Level 1"},{"description":"Arm B - patients with MDS-RAEB or CMML Dose Level 2 - 400 cGy TBI\n\nNONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.\n\nPBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.\n\nIMMUNOSUPPRESSION:\n\nMatched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.\n\nUnrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96.","id":"OG004","title":"Arm B - Dose Level 2"},{"description":"Arm B - patients with MDS-RAEB or CMML Dose Level 3 - 450 cGy TBI\n\nNONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.\n\nPBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.\n\nIMMUNOSUPPRESSION:\n\nMatched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.\n\nUnrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96.","id":"OG005","title":"Arm B - Dose Level 3"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"No patients were enrolled on arms A2 and A3 because dose escalation was never triggered.","reportingStatus":"POSTED","timeFrame":"200 days","title":"Number of Patients With HCT Failure.","type":"PRIMARY","unitOfMeasure":"Participants"}